Hepatic encephalopathy is a disorder detected in patients suffering from cirrhosis. It is a syndrome that occurs in patients with liver dysfunction and is defined as a spectrum of neuropsychiatric abnormalities, after exclusion of brain disease. Hepatic encephalopathy is categorized by intellectual impairment, a depressed level of consciousness, and personality changes. The symptoms of hepatic encephalopathy includes changes in sleeping patterns, disorientation, slurred speech and agitation, drowsiness or confusion, and excitement. The influencing factors for hepatic encephalopathy includes constipation (due to increased nitrogen load), increased protein intake with azotemia, drugs, and hypoxia, gastrointestinal bleeding, and renal dysfunction.
The hepatic encephalopathy market can be segmented by types, treatment, and geography. Based on types, the market can be categorized into Type A, Type B, and Type C. Type A hepatic encephalopathy is related to acute liver failure that leads to rapid deterioration of the liver in patients suffering from pre-existing liver disorders. Acute liver failure that causes complications such as elevated pressure and excessive bleeding in the brain is known as fulminant hepatic failure that requires emergency hospitalization. Type B hepatic encephalopathy is related to portal-systemic bypass deprived of liver disorder. Type B hepatic encephalopathy arises when blood streams around the liver and hence the liver cannot remove or control elements in the blood. Type B generally arises as a result of hereditary abnormalities and as a result of invasive procedures or trauma. Type C hepatic encephalopathy is related to cirrhosis. Cirrhosis is the last phase of chronic liver disease when damaging fibrosis matures. As a result, problems of cirrhosis is reflected in bruising and bleeding easily, jaundice (a yellow discoloration of the skin and whites of the eyes), painful swelling of the legs (edema), fluid build-up in the abdomen (ascites), and portal hypertension (a rise in the blood pressure within a system of veins called the portal venous system).
Furthermore, on the basis of treatments, the hepatic encephalopathy market is categorized into lactulose, antibiotics, probiotics, branched-chain amino acids, and liver transplantation. Lactulose is a synthetic form of sugar that is not absorbed into the body. Lactulose creates an aggressive environment for the bad microbes in the intestine, thus reducing ammonia production in the intestine. Antibiotics such as Rifaximin and Metronidazole may be used to slow down the development of bacteria in the intestine, including bacteria which produce ammonia. Rifaximin is slowly absorbed into the body that helps it to deliberate in the intestines, where it can decrease the growth of unfavorable bacteria. Probiotics or favorable microbes can change the balance of microbes in the intestines, increasing the proportion of favorable bacteria. This can result in reduced levels of ammonia production and other toxic substances. Branched-chain amino acids Valine, Leucine, and Isoleucine can help uphold muscle mass and increase ammonia clearance. Liver transplantation is the final treatment for hepatic encephalopathy wherein the damaged liver is replaced with a healthy donor’s liver. Patients who receive a liver transplant recover their brain function. However, it is important to control and stop incidents of over hepatic encephalopathy, because several incidents of over hepatic encephalopathy can possibly lead to enduring and therefore irreversible brain damage.
On the basis of geography, the global hepatic encephalopathy market is segmented into five key regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the dominant market followed by Europe. Rising patient awareness about different treatment options and increasing demand for treatment is expected to influence the market in North America. The hepatic encephalopathy market is growing due to increasing population, better treatment options, and rising demand for rapid diagnosis globally. Presently, the U.S. is the main country contributing to the global hepatic encephalopathy market, where the financial burden of hepatic encephalopathy is significant. Followed by ascites, hepatic encephalopathy is the second most common cause for hospitalization of cirrhotic patients in the U.S. In addition, the market for global hepatic encephalopathy is expected to expand at a healthy rate in the next few years due to lack of treatment options.
The major players operating in the global hepatic encephalopathy market are Alfa Wassermann S.p.A, Cosmo Pharmaceuticals S.p.A, KannaLife Sciences, Inc., Ocera Therapeutics, Inc., Rebiotix Inc., Spherium Biomed S.L., and Umecrine Cognition AB among others. Increasing competition among key players to develop new therapies for hepatic encephalopathy will drive the market globally.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.